These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 36719059)

  • 1. PNPLA3 I148M and response to treatment for hepatic steatosis: A systematic review.
    Boeckmans J; Gatzios A; Schattenberg JM; Koek GH; Rodrigues RM; Vanhaecke T
    Liver Int; 2023 May; 43(5):975-988. PubMed ID: 36719059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The rs2294918 E434K variant modulates patatin-like phospholipase domain-containing 3 expression and liver damage.
    Donati B; Motta BM; Pingitore P; Meroni M; Pietrelli A; Alisi A; Petta S; Xing C; Dongiovanni P; del Menico B; Rametta R; Mancina RM; Badiali S; Fracanzani AL; Craxì A; Fargion S; Nobili V; Romeo S; Valenti L
    Hepatology; 2016 Mar; 63(3):787-98. PubMed ID: 26605757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Four-Week Omega-3 Supplementation in Carriers of the Prosteatotic PNPLA3 p.I148M Genetic Variant: An Open-Label Study.
    Kuttner CS; Mancina R; Wagenpfeil G; Lammert F; Stokes CS
    Lifestyle Genom; 2019; 12(1-6):10-17. PubMed ID: 31454802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatic patatin-like phospholipase domain-containing 3 levels are increased in I148M risk allele carriers and correlate with NAFLD in humans.
    Ericson E; Bergenholm L; Andréasson AC; Dix CI; Knöchel J; Hansson SF; Lee R; Schumi J; Antonsson M; Fjellström O; Nasr P; Liljeblad M; Carlsson B; Kechagias S; Lindén D; Ekstedt M
    Hepatol Commun; 2022 Oct; 6(10):2689-2701. PubMed ID: 35833455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review article: the emerging role of genetics in precision medicine for patients with non-alcoholic steatohepatitis.
    Carlsson B; Lindén D; Brolén G; Liljeblad M; Bjursell M; Romeo S; Loomba R
    Aliment Pharmacol Ther; 2020 Jun; 51(12):1305-1320. PubMed ID: 32383295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patatin-like phospholipase domain-containing 3 (PNPLA3) I148M (rs738409) affects hepatic VLDL secretion in humans and in vitro.
    Pirazzi C; Adiels M; Burza MA; Mancina RM; Levin M; Ståhlman M; Taskinen MR; Orho-Melander M; Perman J; Pujia A; Andersson L; Maglio C; Montalcini T; Wiklund O; Borén J; Romeo S
    J Hepatol; 2012 Dec; 57(6):1276-82. PubMed ID: 22878467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patatin-like phospholipase domain containing-3 gene I148M polymorphism, steatosis, and liver damage in hereditary hemochromatosis.
    Valenti L; Maggioni P; Piperno A; Rametta R; Pelucchi S; Mariani R; Dongiovanni P; Fracanzani AL; Fargion S
    World J Gastroenterol; 2012 Jun; 18(22):2813-20. PubMed ID: 22719190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pnpla3 silencing with antisense oligonucleotides ameliorates nonalcoholic steatohepatitis and fibrosis in Pnpla3 I148M knock-in mice.
    Lindén D; Ahnmark A; Pingitore P; Ciociola E; Ahlstedt I; Andréasson AC; Sasidharan K; Madeyski-Bengtson K; Zurek M; Mancina RM; Lindblom A; Bjursell M; Böttcher G; Ståhlman M; Bohlooly-Y M; Haynes WG; Carlsson B; Graham M; Lee R; Murray S; Valenti L; Bhanot S; Åkerblad P; Romeo S
    Mol Metab; 2019 Apr; 22():49-61. PubMed ID: 30772256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human hepatocyte PNPLA3-148M exacerbates rapid non-alcoholic fatty liver disease development in chimeric mice.
    Kabbani M; Michailidis E; Steensels S; Fulmer CG; Luna JM; Le Pen J; Tardelli M; Razooky B; Ricardo-Lax I; Zou C; Zeck B; Stenzel AF; Quirk C; Foquet L; Ashbrook AW; Schneider WM; Belkaya S; Lalazar G; Liang Y; Pittman M; Devisscher L; Suemizu H; Theise ND; Chiriboga L; Cohen DE; Copenhaver R; Grompe M; Meuleman P; Ersoy BA; Rice CM; de Jong YP
    Cell Rep; 2022 Sep; 40(11):111321. PubMed ID: 36103835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PNPLA3 I148M Variant Influences Circulating Retinol in Adults with Nonalcoholic Fatty Liver Disease or Obesity.
    Mondul A; Mancina RM; Merlo A; Dongiovanni P; Rametta R; Montalcini T; Valenti L; Albanes D; Romeo S
    J Nutr; 2015 Aug; 145(8):1687-91. PubMed ID: 26136587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term hypercaloric diet exacerbates metabolic liver disease in PNPLA3 I148M animals.
    Su H; Haque M; Becker S; Edlund K; Duda J; Wang Q; Reißing J; Marschall HU; Candels LS; Mohamed M; Sjöland W; Liao L; Drexler SA; Strowig T; Rahnenführer J; Hengstler JG; Hatting M; Trautwein C
    Liver Int; 2023 Aug; 43(8):1699-1713. PubMed ID: 37073116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patatin-like phospholipase domain-containing 3 I148M affects liver steatosis in patients with chronic hepatitis B.
    Viganò M; Valenti L; Lampertico P; Facchetti F; Motta BM; D'Ambrosio R; Romagnoli S; Dongiovanni P; Donati B; Fargion S; Colombo M
    Hepatology; 2013 Oct; 58(4):1245-52. PubMed ID: 23564580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PNPLA3 I148M is involved in the variability in anti-NAFLD response to exenatide.
    Chen Y; Yan X; Xu X; Yuan S; Xu F; Liang H
    Endocrine; 2020 Dec; 70(3):517-525. PubMed ID: 32862405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patatin-Like Phospholipase Domain-Containing Protein 3 I148M and Liver Fat and Fibrosis Scores Predict Liver Disease Mortality in the U.S. Population.
    Unalp-Arida A; Ruhl CE
    Hepatology; 2020 Mar; 71(3):820-834. PubMed ID: 31705824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patatin-like phospholipase domain-containing 3 gene (PNPLA3) polymorphic (rs738409) single nucleotide polymorphisms and susceptibility to nonalcoholic fatty liver disease: A meta-analysis of twenty studies.
    Zhao Y; Zhao W; Ma J; Toshiyoshi M; Zhao Y
    Medicine (Baltimore); 2023 Mar; 102(10):e33110. PubMed ID: 36897668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PPARGC1A rs8192678 G>A polymorphism affects the severity of hepatic histological features and nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease.
    Zhang RN; Shen F; Pan Q; Cao HX; Chen GY; Fan JG
    World J Gastroenterol; 2021 Jul; 27(25):3863-3876. PubMed ID: 34321850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: Results from the WELCOME trial.
    Scorletti E; West AL; Bhatia L; Hoile SP; McCormick KG; Burdge GC; Lillycrop KA; Clough GF; Calder PC; Byrne CD
    J Hepatol; 2015 Dec; 63(6):1476-83. PubMed ID: 26272871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The I148M PNPLA3 polymorphism influences serum adiponectin in patients with fatty liver and healthy controls.
    Valenti L; Rametta R; Ruscica M; Dongiovanni P; Steffani L; Motta BM; Canavesi E; Fracanzani AL; Mozzi E; Roviaro G; Magni P; Fargion S
    BMC Gastroenterol; 2012 Aug; 12():111. PubMed ID: 22898488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IL-6/STAT3 axis dictates the PNPLA3-mediated susceptibility to non-alcoholic fatty liver disease.
    Park J; Zhao Y; Zhang F; Zhang S; Kwong AC; Zhang Y; Hoffmann HH; Bushweller L; Wu X; Ashbrook AW; Stefanovic B; Chen S; Branch AD; Mason CE; Jung JU; Rice CM; Wu X
    J Hepatol; 2023 Jan; 78(1):45-56. PubMed ID: 36049612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between non-alcoholic steatohepatitis, PNPLA3 I148M genotype and bone mineral density in adolescents.
    Mosca A; Fintini D; Scorletti E; Cappa M; Paone L; Zicari AM; Nobili V; Byrne CD
    Liver Int; 2018 Dec; 38(12):2301-2308. PubMed ID: 30176114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.